BrainScope Chief Executive Officer Matt Adams recently sat down with BioHealth Innovation President and CEO Richard Bendis on the BioTalk podcast to explore the future of objective brain health measurement. Their conversation centers on how BrainScope pairs EEG technology with artificial intelligence, giving clinicians and care teams actionable insights right at the point of care.
Building on a foundation of FDA-cleared, point-of-care EEG technology for traumatic brain injury evaluation, BrainScope is expanding its capabilities into a comprehensive AI-driven platform. Adams traces this evolution back to winning the BioHealth Capital Region Crab Trap Competition in 2020, outlining how emerging applications now span concussions, brain bleeds, dementia, and Alzheimer's disease.
Standard neurological evaluations frequently rely on observation rather than hard data. Adams sees a direct clinical need to establish brain electrical activity as an objective vital sign, giving care teams accessible, real-time metrics to support their clinical decisions without the immediate need for specialized imaging.
Leveraging deep learning and an extensive clinical EEG database, BrainScope is identifying markers that could signal Alzheimer's risk years before a standard clinical diagnosis. Adams highlights this research in neurodegenerative disease as a critical step toward longitudinal brain health monitoring and the optimization of central nervous system clinical trials.
Preparing for the next phase of growth, BrainScope is pursuing upcoming clinical partnerships, expanded disease indications, and global commercialization.
Listen to the full conversation about these milestones and the future of real-time brain health measurement on your preferred streaming platform:
• Apple: https://apple.co/45FA0RX
• Spotify: https://bit.ly/3Sbowm5
• iHeart: https://ihr.fm/4qBHsqX
• Amazon: https://amzn.to/4qvM95m
• YouTube: https://bit.ly/4gpBEgN
• TuneIn: https://bit.ly/4xnE2L0